massacre [1:<1 Gastrointestinal System Dyspepsia 1> <1 A double-blind, controlled sleep laboratory study (N=30) in elderly patients compared the effects of DORAL 7.5 mg and 15 mg to that of placebo over a period of 7 days. Both the 7.5 mg and 15 mg doses appeared to be well tolerated. Caution must be used in interpreting this data due to the small size of the study. 7 DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. Benzodiazepines, including DORAL, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g. psychotropic medications, anticonvulsants, antihistamines). Downward dose adjustment of DORAL and/or concomitant CNS depressants may be necessary because of additive effects. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. Administration of benzodiazepines immediately prior to or during childbirth can result in a syndrome of hypothermia, hypotonia, respiratory depression, and difficulty feeding. In addition, infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop dependence, and subsequently withdrawal, during the postnatal period. Although administration of DORAL to pregnant animals did not indicate a risk for adverse effects on morphological development at clinically relevant doses, data for other benzodiazepines suggest the possibility of adverse developmental effects (long-term effects on neurobehavioral and immunological function) in animals following prenatal exposure to benzodiazepines. DORAL should be used during pregnancy only if the potential benefit justifies the potential risk. Developmental toxicity studies of DORAL in mice at doses up to 400 times the human dose (15 mg) revealed no major drug-related malformations. Minor fetal skeletal variations that occurred were delayed ossification of the sternum, vertebrae, distal phalanges and supraoccipital bones, at doses approximately 70 and 400 times the human dose. A developmental toxicity study of DORAL in New Zealand rabbits at doses up to approximately 130 times the human dose demonstrated no effect on fetal morphology or development of offspring. 8.3 Nursing Mothers DORAL and its metabolites are excreted in human milk. Caution should be exercised when administering DORAL to a nursing woman. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use DORAL may cause confusion and over-sedation in the elderly. Elderly patients generally should be started on a low dose of DORAL and observed closely. Elderly and debilitated patients may be more sensitive to benzodiazepines, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. A double-blind controlled sleep laboratory study (N=30) compared the effects of DORAL 7.5 mg and 15 mg to that of placebo over a period of 7 days. Both the 7.5 mg and 15 mg doses appeared to be well tolerated. Caution must be used in interpreting this data due to the small size of the study. 9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substa nce Quazepam is classified as a Schedule IV controlled substance by federal regulation. 9.2 Abuse and Dependence Addiction-prone individuals (e.g. history of drug addiction or alcoholism) should be under careful surveillance when receiving DORAL because of increased risk of abuse and dependence. Benzodiazepine withdrawal symptoms can occur following discontinuation of DORAL [see Warnings and Precautions (5.2) ]. Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug s effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects. Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. 10 OVERDOSAGE Contact a poison control center for up-to-date information on the management of benzodiazepine overdose. Manifestations of DORAL overdose include somnolence, confusion, and coma. General supportive measures should be employed, along with immediate gastric lavage. Dialysis is of limited value. Flumazenil may be useful, but can contribute to the appearance of neurological symptoms including convulsions. Hypotension may be treated by appropriate medical intervention. Animal experiments suggest that forced diuresis or hemodialysis are of little value in treating DORAL overdose. As with the management of intentional overdose with any drug, the possibility of multiple drug ingestion should be considered. 11 DESCRIPTION DORAL contains DORAL, a trifluoroethyl benzodiazepine hypnotic agent, having the chemical name 7-chloro-5- (o-fluoro-phenyl)-1,3-dihydro-1-(2,2,2- trifluoroethyl)-2H-1,4-benzodiazepine-2-thione and the following structural DORAL has the empirical formula C17H11ClF4N2S, and a molecular weight of 386.8. It is a white crystalline compound, soluble in ethanol and insoluble in water. Each DORAL Tablet contains 15 mg of DORAL. The inactive ingredients for Doral Tablets include cellulose, corn starch, FD&C Yellow No. 6 Al Lake, lactose, magnesium stearate, silicon dioxide, and sodium lauryl sulfate. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action DORAL, like other central nervous system agents of the 14-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown. 12.3 Pharmacokinetics Absorption DORAL is rapidly (absorption half-life of about 30 minutes) and well absorbed from the gastrointestinal tract. The peak plasma concentration of DORAL is approximately 20 ng/mL after a 15 mg dose and occurs at about 2 hours. Metabolism DORAL, the active parent compound, is extensively metabolized in the liver; two of the plasma metabolites are 2-oxo DORAL and N-desalkyl-2-oxo DORAL. All three compounds show CNS depressant activity. Distribution The degree of plasma protein binding for DORAL and its two major metabolites is greater than 95%. Elimination Following administration of 14 C-DORAL, 31% of the dose appeared in the urine and 23% in the feces over five days; only trace amounts of unchanged drug were present in the urine. The mean elimination half-life of DORAL and 2-oxo DORAL is 39 hours and that of N-desalkyl-2-oxo DORAL is 73 hours. Steady-state levels of DORAL and 2-oxo DORAL are attained by the seventh daily dose and that of N-desalkyl-2-oxo DORAL by the thirteenth daily dose. Special Populations Geriatrics: The pharmacokinetics of DORAL and 2-oxo DORAL in geriatric subjects are comparable to those seen in young adults; as with desalkyl metabolites of other benzodiazepines, the elimination half-life of N-desalkyl-2-oxo DORAL in geriatric patients is about twice that of young adults. Drug Interactions Bupropion (a CYP2B6 substrate): Co-administration of a single dose of 150 mg Bupropion Hydrochloride XL with steady state DORAL did not significantly affect the AUC and Cmax of bupropion or its primary metabolite, hydroxybupropion. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis DORAL showed no evidence of carcinogenicity in oral carcinogenicity studies in mice and hamsters. Mutagenesis DORAL was negative in the bacterial reverse mutation (Ames) assay and equivocal in the mouse lymphoma tk assay. Impairment of Fertility Reproduction studies in mice conducted with DORAL at doses equal to 60 and 180 times the human dose of 15 mg produced slight reductions in fertility rate. Similar reductions in fertility rate have been reported in mice dosed with other benzodiazepines, and is believed to be related to the sedative effects of these drugs at high doses 14 CLINICAL STUDIES The effectiveness of DORAL was established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of DORAL was established in chronic insomnia in a sleep laboratory (polysomnographic) study of 28 nights duration. In the sleep laboratory study, DORAL significantly decreased sleep latency and total wake time, and significantly increased total sleep time and percent sleep time, for one or more nights. DORAL 15 mg was effective on the first night of administration. Sleep latency, total wake time and wake time after sleep onset were still decreased and percent sleep time was still increased for several nights after the drug was discontinued. Percent slow wave sleep was decreased, and REM sleep was essentially unchanged. No transient sleep disturbance, such as rebound insomnia, was observed after withdrawal of the drug in sleep laboratory studies in 12 patients using 15 mg doses. A double-blind, controlled sleep laboratory study (N=30) in elderly patients compared the effects of DORAL 7.5 mg and 15 mg to that of placebo over a period of 7 days. Both the 7.5 mg and 15 mg doses appeared to be effective. Caution must be used in interpreting this data due to the small size of the study. 16 HOW SUPPLIED / STORAGE AND HANDLING Doral Tablets, 15 mg, functionally scored, capsule-shaped, light orange, slightly white speckled tablets, impressed with the product identification number 15 on one side of the tablet, and the name (DORAL) on the other. 15 mg Bottles of 100 NDC 61825-165-10 Store Doral Tablets at controlled room temperature 20 -25 C (68 -77 F). 17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling ( Medication Guide ). Inform patients and caregivers that potentially fatal additive effects may occur if DORAL is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.1) , Drug Interactions (7) ] Inform patients about the benefits and risks of DORAL, stressing the importance of use as directed. Assist patients in understanding the Medication Guide and instruct them to read it with each prescription refill. CNS depressant Effects and Next-Day Impairment Tell patients that DORAL can cause next-day impairment, even in the absence of symptoms. Caution patients against driving or engaging in other hazardous activities or activities requiring complete mental alertness when using DORAL. Tell patients that daytime impairment may persist for several days following discontinuation of DORAL. Withdrawal Instruct patients to contact you before stopping or decreasing the dose of DORAL, because withdrawal symptoms can occur. Abnormal thinking and behavior change Instruct patients that sedative hypnotics can cause abnormal thinking and behavior change, including sleep-driving and other complex behaviors while not being fully awake (preparing and eating food, making phone calls, or having sex). Tell patients to call you immediately if they develop any of these symptoms. Severe Allergic Reactions Inform patients that severe allergic reactions can occur from DORAL. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if these occur. Suicide Tell patients that DORAL can worsen depression, and to immediately report any suicidal thoughts. Alcohol and other drugs Ask patients about alcohol consumption, medicines they are taking now, and drugs they may be taking without a prescription. Advise patients that alcohol generally should not be used during treatment with DORAL. Pregnancy Instruct patients to inform you if they are nursing or pregnant, or may become pregnant while taking DORAL. Tolerance, Abuse, and Dependence Tell patients not to increase the dose of DORAL on their own, and to inform you if they believe the drug does not work . Galt Pharmaceuticals, LLC. Atlanta, GA 30339 Phone: (855) 965-2783 Fax (855) 276-4063 Manufactured by: Meda Pharmaceuticals, Inc. Somerset, NJ 08873-4120 Printed in USA. IN-04052-02 Rev. 08/2017 MEDICATION GUIDE DORAL (quazepam tablets, USP) /CAPSULES C-IV Read this Medication Guide before you start taking DORAL and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. You and your doctor should talk about DORAL when you start taking it and at regular checkups. What is the most important information I should know about DORAL? After taking DORAL, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with DORAL. Reported activities include: driving a car ( sleep-driving ) making and eating food talking on the phone having sex walking Important: 1. Take DORAL exactly as prescribed Do not take more DORAL than prescribed. Take DORAL right before you get in bed, not sooner. 2. Do not take DORAL if you: drink alcohol take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take DORAL with your other medicines cannot get a full night s sleep 3. Call your doctor right away if you find out that you have done any of the above activities after taking DORAL. What is DORAL? DORAL is a sleep medicine. DORAL is used in adults for the short-term treatment of the symptom of trouble falling asleep from insomnia. DORAL does not treat other symptoms of insomnia which include waking up too early in the morning and waking up often during the night. DORAL is not for children. DORAL is a federally controlled substance (C-IV) because it can be abused or lead to dependence. Keep DORAL in a safe place to prevent misuse and abuse. Selling or giving away DORAL may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs. Who should not take DORAL? Do not take DORAL if you are allergic to anything in it. See the end of this Medication Guide for a complete list of ingredients in DORAL. DORAL may not be right for you. Before starting DORAL, tell your doctor about all of your health conditions, including if you: have a history of depression, mental illness, or suicidal thoughts have a history of drug or alcohol abuse or addiction have kidney or liver disease have a lung disease or breathing problems are pregnant, planning to become pregnant, or breastfeeding Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact, sometimes causing side effects. Do not take DORAL with other medicines that can make you sleepy. Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine. How should I take DORAL? Take DORAL exactly as prescribed. Do not take more DORAL than prescribed for you. Take DORAL right before you get into bed. Or you can take DORAL after you have been in bed and have trouble falling asleep. Do not take DORAL with or right after a meal. Do not take DORAL unless you are able to get a full night s sleep before you must be active again. Call your healthcare provider if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problem. If you take too much DORAL or overdose, call your doctor or poison control center right away, or get emergency treatment. What are the possible side effects of DORAL? Serious side effects of DORAL include: getting out of bed while not being fully awake and do an activity that you do not know you are doing. (See What is the most important information I should know about DORAL? ) abnormal thoughts and behavior. Symptoms include more outgoing or aggressive behavior than normal, confusion, agitation, hallucinations, worsening of depression, and suicidal thoughts or actions. memory loss anxiety severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking DORAL. Call your doctor right away if you have any of the above side effects or any other side effects that worry you while using DORAL. Common side effects of DORAL include: drowsiness headache fatigue dizziness dry mouth upset stomach You may still feel drowsy the next day after taking DORAL. Do not drive or do other dangerous activities after taking DORAL until you feel fully awake. You may have withdrawal symptoms for 1 to 2 days when you stop taking DORAL. Withdrawal symptoms include trouble sleeping, unpleasant feelings, stomach and muscle cramps, vomiting, sweating, shakiness, and seizures. These are not all the side effects of DORAL. Ask your doctor or pharmacist for more information. How should I store DORAL? Store DORAL at room temperature between 68 and 77 F (20 to 25 C). Protect from light. Keep DORAL and all medicines out of the reach of children. General Information about DORAL Medicines are sometimes prescribed for purposes not mentioned in a Medication Guide. Do not use DORAL for a condition for which it was not prescribed. Do not give DORAL to other people, even if they have the same condition. It may harm them and it is against the law. This Medication Guide summarizes the most important information about DORAL. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about DORAL that was written for healthcare professionals. If you would like more information, contact Galt Pharmaceuticals at 1-855-965-2783 or visit http://www.doralrx.com What are the ingredients in DORAL? Active Ingredient: quazepam Inactive Ingredients: cellulose, corn starch, FD&C Yellow No. 6 Al Lake, lactose, magnesium stearate, silicon dioxide, and sodium lauryl sulfate. Rx only Distributed by: Galt Pharmaceuticals, LLC Marietta, GA 30339 This Medication Guide has been approved by the U.S. Food and Drug Administration. IS-1500-01 Rev. 08/17 PRINCIPAL DISPLAY PANEL NDC 61825-165-10 Doral (quazepam tablets, USP) 15 mg 100 Tablets Rx Only DORAL quazepam tablet Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:61825-165 Route of Administration ORAL DEA Schedule CIV Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength QUAZEPAM (QUAZEPAM) QUAZEPAM 15 mg Inactive Ingredients Ingredient Name Strength POWDERED CELLULOSE STARCH, CORN FD&C YELLOW NO. 6 LACTOSE MAGNESIUM STEARATE SILICON DIOXIDE SODIUM LAURYL SULFATE Product Characteristics Color ORANGE (light orange) Score 2 pieces Shape CAPSULE Size 12mm Flavor Imprint Code 15;DORAL Contains Packaging # Item Code Package Description 1 NDC:61825-165-10 100 TABLET in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018708 07/19/2017 Labeler - Galt Pharmaceuticals LLC (079214973) Revised: 08/2017 Galt Pharmaceuticals LLC Next Interactions Print this page Add to My Med List More about Doral (quazepam) Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Images Drug Interactions Support Group Pricing & Coupons En Español 3 Reviews Add your own review/rating Drug class: benzodiazepines Consumer resources Doral Doral (Advanced Reading) Professional resources Quazepam (FDA) Related treatment guides Insomnia> ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out 4 CSA Schedule Some potential for abuse 10 + years Approval History FDA approved 1985 Drug Class Benzodiazepines Related Drugs benzodiazepines alprazolam , clonazepam , Xanax , lorazepam , diazepam , temazepam Insomnia melatonin , lorazepam , zolpidem , amitriptyline , Ambien , temazepam , Ativan , diphenhydramine , doxepin , Elavil , Restoril , Ibuprofen PM , Belsomra , Lunesta , eszopiclone , Rozerem , triazolam , zaleplon , doxylamine , Sonata , Silenor , Halcion , flurazepam , ramelteon , More... Doral Rating 3 User Reviews 9.5 /10 3 User Reviews 9.5 Rate it! Doral Images Doral 7.5 mg (DORAL 7.5) View larger images} } all of the sudden
in vogue Doral Tablets at this time
EmoticonEmoticon